TICKERNERD
Menu
CALCCALCHealthcare · Biotechnology

CALC Stock Forecast: CalciMedica, Inc. Price Predictions for 2026-2027

Last close, 18 Sept 2026
$1.92

The 4 Wall Street analysts covering CalciMedica, Inc. hold a median 12-month price target of $45 — +2243.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 27 of 100 as at 19 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$13.1M
Ticker Nerd rank
27 / 100
Median analyst target
$45
Analysts covering
4
Revenue$0.0
Operating income−$4.0M
Net income−$7.7M
Free cash flow−$4.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Ticker Nerd rank

CALC stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores CalciMedica, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026
27 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
91
Growth
71
Revisions
66
Volatility
62
Accruals
53
Quality
12
Issuance
10
Value
9
Momentum
3

Size (91): Smaller than most of the companies we track.

Momentum (3): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CALC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CALC, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says4 analysts
3 Buy1 Hold0 Sell
Low $30Median $45High $75

The green dot is the last close — the median target sits +2243.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
20 Aug 2026GuggenheimInitiatesBuy$9.00
5 Mar 2026OppenheimerMaintainsOutperform$20 → $10
5 Mar 2026OppenheimerMaintainsOutperform—
29 Jan 2026HC Wainwright & Co.DowngradeNeutral—
15 May 2025HC Wainwright & Co.ReiteratesBuy—
1 Apr 2025HC Wainwright & Co.ReiteratesBuy—
4 Mar 2025HC Wainwright & Co.ReiteratesBuy—
17 Dec 2024LUCID CAPITAL MARKETSInitiatesBuy—
14 Nov 2024HC Wainwright & Co.ReiteratesBuy—
4 Nov 2024HC Wainwright & Co.MaintainsBuy—
13 Aug 2024HC Wainwright & Co.ReiteratesBuy—
10 July 2024OppenheimerMaintainsOutperform—
9 July 2024HC Wainwright & Co.ReiteratesBuy—
27 June 2024HC Wainwright & Co.ReiteratesBuy—
14 May 2024HC Wainwright & Co.ReiteratesBuy—
1 Apr 2024HC Wainwright & Co.ReiteratesBuy—
1 Apr 2024OppenheimerMaintainsOutperform—
13 Mar 2024HC Wainwright & Co.ReiteratesBuy—
16 Feb 2024JonesTradingInitiatesBuy—
13 Feb 2024HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CALC appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

CALC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
1
Fundamentals

CalciMedica, Inc. (CALC) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.3×

Cheaper than 72% of US stocks

Price / sales
—
Price / book
2.1×

Cheaper than 43% of US stocks

EV / EBITDA
−0.2×

Cheaper than 62% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−365.7%

Higher than 4% of US stocks

Return on assets
−63.6%

Higher than 6% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

CalciMedica, Inc. (CALC) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • CalciMedica, Inc. has a market value of $13.1M and an enterprise value of $3.7M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$21.2M.

  • Free cash flow in the twelve months to 30 June 2026: −$19.1M.

  • Shares outstanding: 30.7M.

  • Trailing P/E: 0.3×; forward P/E: −1.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • CalciMedica, Inc. employs 15 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Sept 2026

Data provided by Twelve Data

Peers

CALC vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CALCCalciMedica, Inc.$13.1M
27
GTBPGT Biopharma, Inc.$12.9M
16
PLURPluri, Inc.$13.3M
15
INTSIntensity Therapeutics, Inc.$13.4M
23
ADILAdial Pharmaceuticals, Inc.$12.8M
21
ENLVEnlivex Ltd.$13.6M
41
BIVIBioVie, Inc.$13.6M
25

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own CalciMedica, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CALC news & analysis

CalciMedica to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

GlobeNewsWire · 8 Sept 2026neutral

CalciMedica announced that its management will present and participate in one-on-one investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference. The company, a clinical-stage biopharmaceutical firm developing CRAC channel inhibition therapies, disclosed this participation on September 8, 2026.

Why it matters — Conference participation offers CalciMedica a platform to present its pipeline to investors, which could increase visibility among current and potential shareholders.

CalciMedica Announces One-for-Five Reverse Stock Split

GlobeNewsWire · 27 Aug 2026neutral

CalciMedica announced it will effect a one-for-five reverse stock split of its issued and outstanding common stock, effective at 5:00 p.m. on August 27, 2026. The company is a clinical-stage biopharmaceutical firm developing CRAC channel inhibition therapies.

Why it matters — A reverse stock split changes the number of shares outstanding and the per-share price, so CALC shareholders would want to note the revised share count and price structure.

CalciMedica Announces FDA Alignment on Phase 2b Trial Design for Auxora in Acute Pancreatitis and Identifies Disease's First Potential Registrational Endpoints

PRNewsWire · 29 July 2026positive

CalciMedica announced that the FDA has aligned with the company on the Phase 2b trial design and endpoints for Auxora in acute pancreatitis, including new-onset severe respiratory failure as the primary endpoint and a patient enrichment strategy using elevated lactate dehydrogenase (LDH).

Why it matters — This FDA alignment moves Auxora's registration program forward and establishes the first potential registrational endpoints for acute pancreatitis, a key regulatory milestone for the company.

FAQ

Frequently asked questions about CALC stock

What is the CALC stock price forecast for 2026-2027?

The 4 Wall Street analysts covering CalciMedica, Inc. have a median 12-month price target of $45, with estimates ranging from $30 to $75. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CALC stock a buy right now?

Of the 4 analysts covering CalciMedica, Inc., 3 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks CalciMedica, Inc. 27 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CALC?

As at 19 Sept 2026, CalciMedica, Inc. ranks 27 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (91 of 100).

Will CALC stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +2243.8% from the last close, and Ticker Nerd's factor model ranks CalciMedica, Inc. 27 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CALC stock forecast for 2030?

No analyst covering CalciMedica, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CALC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $30 to $75 over the next 12 months.

What does CalciMedica, Inc. do?

CalciMedica, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies that target calcium release-activated calcium (CRAC) channels for serious inflammatory, immunologic, and cardiopulmonary diseases.

What is the latest news on CALC?

The most recent item we track (GlobeNewsWire, 8 Sept 2026): "CalciMedica to Participate in the H.C. Wainwright 28th Annual Global Investment Conference". CalciMedica announced that its management will present and participate in one-on-one investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference. The company, a clinical-stage biopharmaceutical firm developing CRAC channel inhibition therapies, disclosed this participation on September 8, 2026.

Company

About CalciMedica, Inc.

CalciMedica, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies that target calcium release-activated calcium (CRAC) channels for serious inflammatory, immunologic, and cardiopulmonary diseases. The company’s lead candidate, Auxora, is an intravenous small-molecule CRAC channel inhibitor being evaluated in multiple settings, including acute pancreatitis, acute kidney injury, and other severe inflammatory conditions. CalciMedica also develops an oral CRAC channel inhibitor program aimed at chronic inflammatory and immunologic diseases. Its current work centers on drug discovery and clinical development for conditions where inflammation and direct cellular injury drive high unmet medical need. Based in La Jolla, California, CalciMedica plays a specialized role in the biotechnology market by advancing a differentiated calcium-channel inhibition platform for acute and chronic disease areas.

CEO Dr. A. Rachel Leheny Ph.D. · 15 employees · United States · https://calcimedica.com